The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: Results from the MRC RT01 trial (ISRCTN47772397)

Radiotherapy and Oncology

Volumn 83, Issue 1, 2007, Pages 31-41

  Dearnaley, David P ^a   Sydes, Matthew R ^b   Langley, Ruth E ^b   Graham, John D ^c   Huddart, Robert A ^a   Syndikus, Isabel ^d   Matthews, John H L ^e   Scrase, Christopher D ^f   Jose, Chakiath C ^e   Logue, John ^g   Stephens, Richard J ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b MRC CLINICAL TRIALS UNIT   (United Kingdom)

^c BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^d CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^e AUCKLAND CITY HOSPITAL   (New Zealand)

^f IPSWICH HOSPITAL   (United Kingdom)

^g CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Conformal radiotherapy; Dose escalation; Phase III trial; Prostate cancer; Radiation toxicity

Indexed keywords

ANDROGEN; ANTIANDROGEN; GONADORELIN;

AGED; ARTICLE; BLADDER; BLADDER DISCOMFORT; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENTEROPATHY; HEMATURIA; HORMONAL THERAPY; HUMAN; INTESTINE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; QUESTIONNAIRE; RADIATION DOSE; RADIATION INJURY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RECTUM DISEASE; SEXUAL BEHAVIOR; SEXUAL FUNCTION; SHORT FORM 36; URETHRA STRICTURE; URINARY FREQUENCY;

AGED; ANDROGEN ANTAGONISTS; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RANDOMIZED CONTROLLED TRIALS; RECTUM; URINARY BLADDER;

EID: 34047159109     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2007.02.014     Document Type: Article

References (35)

1. Carroll P., Lee K., Fuks Z., and Kantoff P. Prostate cancer. In: de Vita V., Hellman S., and Rosenberg S. (Eds). Cancer: principles and practice of oncology. 6th ed. (1996), Lippincott, Williams and Wilkins, Philadelphia 1418-1479
2. Mangar S.A., Huddart R.A., Parker C.C., Dearnaley D.P., Khoo V.S., and Horwich A. Technological advances in radiotherapy for the treatment of localised prostate cancer. Eur J Cancer 41 (2005) 908-921
3. Dearnaley D.P., Khoo V.S., Norman A.R., Meyer L., Nahum A., Tait D., et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 353 (1999) 267-272
4. Pollack A., Zagars G.K., Smith L.G., Lee J.J., von Eschenbach A.C., Antolak J.A., et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 18 (2000) 3904-3911
5. Zietman A.L., DeSilvio M.L., Slater J.D., Rossi Jr. C.J., Miller D.W., Adams J.A., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294 (2005) 1233-1239
6. Peeters S.T., Heemsbergen W.D., van Putten W.L., Slot A., Tabak H., Mens J.W., et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 61 (2005) 1019-1034
7. Dearnaley D.P., Hall E., Lawrence D., Huddart R.A., Eeles R., Nutting C.M., et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer 92 (2005) 488-498
8. Sydes M.R., Stephens R.J., Moore A.R., Aird E.G., Bidmead A.M., Fallowfield L.J., et al. Implementing the UK Medical Research Council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer. Radiother Oncol 72 (2004) 199-211
9. UICC. TNM classification of malignant tumours (International Union against Cancer). Geneva: Springer-Verlag; 1997.
10. Diaz A., Roach III M., Marquez C., Coleman L., Pickett B., Wolfe J.S., et al. Indications for and the significance of seminal vesicle irradiation during 3D conformal radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 30 (1994) 323-329
11. Khoo V.S., Bedford J.L., Webb S., and Dearnaley D.P. An evaluation of three-field coplanar plans for conformal radiotherapy of prostate cancer. Radiother Oncol 55 (2000) 31-40
12. Khoo V.S., Bedford J.L., Webb S., and Dearnaley D.P. Class solutions for conformal external beam prostate radiotherapy. Int J Radiat Oncol Biol Phys 55 (2003) 1109-1120
13. Pickett B., Roach III M., Horine P., Verhey L., and Phillips T.L. Optimization of the oblique angles in the treatment of prostate cancer during six-field conformal radiotherapy. Med Dosim 19 (1994) 237-254
14. Griffiths S., Stanley S., Sydes M., and and RT01 Radiographers Group on behalf of all the RT01 Collaborators. Recommendations on best practice for radiographer set up of conformal radiotherapy treatment for patients with prostate cancer: experience developed during the MRC RT01 trial (ISRTCN 47772397). J Radiother Practice 4 (2005) 107-117
15. Moore A.R., Warrington A.P., Aird E.G., Bidmead A.M., and Dearnaley D.P. A versatile phantom for quality assurance in the UK Medical Research Council (MRC) RT01 trial (ISRCTN47772397) in conformal radiotherapy for prostate cancer. Radiother Oncol 80 (2006) 82-85
16. Seddon B., Bidmead M., Wilson J., Khoo V., and Dearnaley D. Target volume definition in conformal radiotherapy for prostate cancer: quality assurance in the MRC RT-01 trial. Radiother Oncol 56 (2000) 73-83
17. LENT SOMA tables. Radiother Oncol 1995;35:17-60.
18. Ware Jr. J.E., and Sherbourne C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30 (1992) 473-483
19. Litwin M.S., Hays R.D., Fink A., Ganz P.A., Leake B., and Brook R.H. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care 36 (1998) 1002-1012
20. Esper P., Mo F., Chodak G., Sinner M., Cella D., and Pienta K.J. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 50 (1997) 920-928
21. Beckendorf V., Guerif S., Le Prise E., Cosset J.M., Lefloch O., Chauvet B., et al. The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity. Int J Radiat Oncol Biol Phys 60 (2004) 1056-1065
22. Pinkawa M., Fischedick K., Asadpour B., Gagel B., Piroth M.D., and Eble M.J. Low-grade toxicity after conformal radiation therapy for prostate cancer - impact of bladder volume. Int J Radiat Oncol Biol Phys 64 (2006) 835-841
23. Ryu J.K., Winter K., Michalski J.M., Purdy J.A., Markoe A.M., Earle J.D., et al. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy). Int J Radiat Oncol Biol Phys 54 (2002) 1036-1046
24. Michalski J.M., Winter K., Purdy J.A., Parliament M., Wong H., Perez C.A., et al. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V. Int J Radiat Oncol Biol Phys 62 (2005) 706-713
25. Laverdiere J., Gomez J.L., Cusan L., Suburu E.R., Diamond P., Lemay M., et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 37 (1997) 247-252
26. Laverdiere J., Nabid A., de Bedoya L.D., Ebacher A., Fortin A., Wang C.S., et al. The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. J Urol 171 (2004) 1137-1140
27. Porter A.T., Elhilali M., Manji M., Grignon D., Thomas G., Kostashuk G.E., et al. A phase III randomised trial to evaluate the efficacy of neoadjuvant therapy prior to curative radiotherapy in locally advanced prostate cancer patients. A Canadian Urologic Oncology Group Study. Proc Am Soc Clin Onc 17 (1997) 315A
28. Pilepich M.V., Winter K., John M.J., Mesic J.B., Sause W., Rubin P., et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50 (2001) 1243-1252
29. D'Amico A.V., Manola J., Loffredo M., Renshaw A.A., DellaCroce A., and Kantoff P.W. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 292 (2004) 821-827
30. Denham J.W., Steigler A., Lamb D.S., Joseph D., Mameghan H., Turner S., et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 6 (2005) 841-850
31. Roach M., Lu J., Pilepich M.V., Asbell S.O., Mohiuddin M., Terry R., et al. Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys 47 (2000) 617-627
32. Stephens R.J., Dearnaley D.P., Cowan R., Sydes M., Naylor S., Fallowfield L., et al. The quality of life of men with locally advanced prostate cancer during neoadjuvant hormone therapy: data from the Medical Research Council RT01 trial (ISRCTN 47772397). BJU Int 99 (2007) 301-310
33. Valicenti R.K., Winter K., Cox J.D., Sandler H.M., Bosch W., Vijayakumar S., et al. RTOG 94-06: is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity. Int J Radiat Oncol Biol Phys 57 (2003) 614-620
34. Lamb D.S., Denham J.W., Mameghan H., Joseph D., Turner S., Matthews J., et al. Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer. Radiother Oncol 68 (2003) 255-267
35. Peeters S.T., Heemsbergen W.D., Koper P.C., van Putten W.L., Slot A., Dielwart M.F., et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24 (2006) 1990-1996